

This is a repository copy of *Usefulness of EQ-5D in Assessing Health Status in Primary Care Patients with Major Depressive Disorder*.

White Rose Research Online URL for this paper:

<https://eprints.whiterose.ac.uk/1037/>

---

**Article:**

Sapin, C., Fantino, B., Nowicki, M.L. et al. (1 more author) (2004) Usefulness of EQ-5D in Assessing Health Status in Primary Care Patients with Major Depressive Disorder. Health and Quality of Life Outcomes. ISSN 1477-7525

<https://doi.org/10.1186/1477-7525-2-20>

---

**Reuse**

Items deposited in White Rose Research Online are protected by copyright, with all rights reserved unless indicated otherwise. They may be downloaded and/or printed for private study, or other acts as permitted by national copyright laws. The publisher or other rights holders may allow further reproduction and re-use of the full text version. This is indicated by the licence information on the White Rose Research Online record for the item.

**Takedown**

If you consider content in White Rose Research Online to be in breach of UK law, please notify us by emailing [eprints@whiterose.ac.uk](mailto:eprints@whiterose.ac.uk) including the URL of the record and the reason for the withdrawal request.

Research

Open Access

## Usefulness of EQ-5D in Assessing Health Status in Primary Care Patients with Major Depressive Disorder

Christophe Sapin<sup>\*1</sup>, Bruno Fantino<sup>2</sup>, Marie-Laure Nowicki<sup>3</sup> and Paul Kind<sup>4</sup>

Address: <sup>1</sup>Altipharm, Paris, France, <sup>2</sup>Agoras, Lyon, France, <sup>3</sup>H. Lundbeck A/S, Paris, France and <sup>4</sup>Centre for Health Economics, University of York, England, UK

Email: Christophe Sapin<sup>\*</sup> - christophe.sapin@free.fr; Bruno Fantino - agoras@wanadoo.fr; Marie-Laure Nowicki - mlno@lundbeck.com; Paul Kind - pk1@york.ac.uk

<sup>\*</sup> Corresponding author

Published: 05 May 2004

Received: 08 March 2004

*Health and Quality of Life Outcomes* 2004, **2**:20

Accepted: 05 May 2004

This article is available from: <http://www.hqlo.com/content/2/1/20>

© 2004 Sapin et al; licensee BioMed Central Ltd. This is an Open Access article: verbatim copying and redistribution of this article are permitted in all media for any purpose, provided this notice is preserved along with the article's original URL.

### Abstract

**Objectives:** Major depressive disorder (MDD) is a prevalent psychiatric disorder associated with impaired patient functioning and reductions in health-related quality of life (HRQL). The present study describes the impact of MDD on patients' HRQL and examines preference-based health state differences by patient features and clinical characteristics.

**Methods:** 95 French primary care practitioners recruited 250 patients with a DSM-IV diagnosis of MDD for inclusion in an eight-week follow-up cohort. Patient assessments included the Montgomery Asberg Depression Rating Scale (MADRS), the Clinical Global Impression of Severity (CGI), the Short Form-36 Item scale (SF-36), the Quality of Life Depression Scale (QLDS) and the EuroQoL (EQ-5D).

**Results:** The mean EQ-5D utility at baseline was 0.33, and 8% of patients rated their health state as worse than death. There were no statistically significant differences in utilities by demographic features. Significant differences were found in mean utilities by level of disease severity assessed by CGI. The different clinical response profiles, assessed by MADRS, were also revealed by EQ-5D at endpoint: 0.85 for responders remitters, 0.72 for responders non-remitter, and 0.58 for non-responders. Even if HRQL and EQ-5D were moderately correlated, they shared only 40% of variance between baseline and endpoint.

**Conclusions:** Self-reported patient valuations for depression are important patient-reported outcomes for cost-effectiveness evaluations of new antidepressant compounds and help in further understanding patient compliance with antidepressant treatment.

### Introduction

Major depressive disorder (MDD) is common in primary care patients [1] with a lifetime prevalence rate in the French population of 10–25% in women and 5–12% in men [2]. Depression is associated with marked decreases

in functioning, well being and health-related quality of life (HRQL) [3,4], and an increases in disability days [5], use of health services and overall societal costs [6]. Antidepressant treatments are effective in reducing depression

severity [7,8] and in increasing patient functioning and HRQL [9,10].

The Washington Panel on Cost-Effectiveness in Health and Medicine recommended the use of HRQL in the evaluation of health care interventions [11]. For this purpose, HRQL measurement needs to express patient health status on a scale where perfect health and death are valued 1 and 0 respectively. When such quality of life data are combined with corresponding data on the quantity of life, then the consequences of treatment are measured in units of Quality-Adjusted Life Years (QALYs) [12]. Where QALYs are calculated for social decision making purposes then the HRQL measures used to make the quality adjustment should be based on the preferences of the population as a whole. Such social preferences are only available for a limited number of HRQL measures and for a limited number of countries. EQ-5D is one such measure that has been calibrated in this way.

Studies of physical illnesses have suggested that patient's values for their own health state affect decisions concerning treatment and its outcomes [13-15]. Several studies focused on establishing utility scores for a variety of health states in various mental illnesses, including schizophrenia [16], depression in primary care [17], temporary states of depression [18,19] and treatment-related side effects [20,21]. Health states in depression have been characterised by the presence or absence of symptoms, and depressed patients are usually categorised as responders and remitters using classical rating scales [22]. As responders sometimes present residual depressive symptoms, we classify patients as "Responder remitters", "Responders non-remitter" and "Non-responders".

The objectives of this paper are to describe the impact on HRQL of patients with MDD treated in a primary care setting, and to examine variations in terms of patients' demographic and clinical characteristics.

## Material and methods

### Design and patient sample

This national, multicentre, prospective, non-comparative cohort study was designed so as to reproduce the guidelines for management of depression in primary care. The scheduled follow-up period was two months, with assessments at baseline (D0), four weeks later (D28) and eight weeks later (D56).

The patients included in this study were recruited from an outpatient population, aged 18 and older, who consulted general practitioners for a new episode of MDD according to the DSM-IV [23]), and who were not treated with any antidepressant before inclusion. Patients whose symptomatology suggested schizophrenia or other psychotic

symptoms, according to DSM-IV, were not included in this study. According to their experience and daily practice, general practitioners initiated an antidepressant treatment at baseline.

### Data collection

#### Patients' characteristics

Patient profiles were created at baseline by recording age, gender, lifestyle, place of residence, socio-professional category and current professional status.

#### Clinical measures

Physicians assessed the severity of depressive symptoms using the Montgomery-Asberg Depression Rating Scale (MADRS) [24] and the Clinical Global Impression of Severity (CGI-S) scale. The CGI was rated by physicians on a seven-point Likert scale ranging from 1 = "Normal, not ill at all" to 7 = "Among the most ill patients".

Qualitative outcomes derived from rating scales, like response to treatment or remission, are usually used in both clinical trials and economic evaluations of new antidepressant agents [22]. Using MADRS scores at D56, patients were classified into two groups: those that had scores lower or equal to 12 were considered as "Remitters", the others were considered as "Non-remitters". Patients who had a decrease of at least 50% in relation to baseline score were considered as "Responder", whereas the others were "Non-responders". These two patients groupings led to the creation of three mutually exclusive groups: "Responder remitters", "Responders non-remitter" and "Non-responders".

#### Patient Reported Outcomes

The outcome measures used in this study were the 36-item Short-Form Health Survey (SF-36), the Quality of Life in Depression Scale (QLDS) and the EQ-5D.

The SF-36 is a generic HRQL measure consisting of eight dimensions assessing physical functioning (PF), role limitations due to physical problems (RP), bodily pain (BP), general health (GH), vitality (VT), mental health (MH), role limitations due to emotional problems (RE) and social functioning (SF) [25]. Two summary scores also assess both physical (PCS) and mental (MCS) facets [26]. All scale scores range from 0 (the worst HRQL) to 100 (the best HRQL).

The QLDS is a 34-item depression-specific HRQL instrument that assesses the ability and capacity of individuals to satisfy their daily needs [27,28]. Each item is answered by Yes or No. An overall HRQL score is obtained by summing the 34 items. The results range from 0 (the highest HRQL) to 34 (the lowest HRQL).

**Table 1: Patient sociodemographics and clinical characteristics**

	Frequency	Percentage
<b>Gender <sup>a</sup></b>		
Male	69	27.7
Female	180	72.3
<b>Professional status <sup>b</sup></b>		
Farmer	1	0.4
Craftsman	15	6.1
Manager	26	10.6
Intermediate profession	44	17.9
Employee	78	31.7
Manual labourer	19	7.7
Retired	27	11.0
Other	36	14.6
<b>Place of residence <sup>c</sup></b>		
Urban area	185	74.3
Rural area	64	25.7
<b>CGI-Severity at baseline</b>		
First signs	0	0.0
Slightly ill	6	2.4
Moderately ill	36	14.4
Markedly ill	173	69.2
Seriously ill	35	14.0
<b>Clinical response</b>		
Responder remitters	144	64.3
Responders non-remitter	34	15.2
Non-responders	46	20.5

<sup>a</sup> missing value = 1; <sup>b</sup> missing values = 4; <sup>c</sup> missing values = 26.

EQ-5D is a generic measure of HRQL in which health status is defined in terms of 5 dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression [29]. Each dimension has three qualifying levels of response roughly corresponding to 'no problems', 'some difficulties/problems', and 'extreme difficulties'. EQ-5D defines a total of 243 unique health states. The importance of each of these states can be determined in a number of different ways. For the purpose of cost-utility analysis and other situations where the consequences of treatment are measured in terms of QALYs, these weights are typically established using utility measurement techniques such as Standard Gamble or Time Trade-Off (TTO) [12]. For the purposes of this present study, TTO weights elicited from a large national survey of the UK population were used [30]. Information collected using EQ-5D can be reported in terms of its individual dimensions and as a single index score (EQ-5D<sub>ST</sub>).

### Data analysis

Continuous variables were expressed by means and standard deviations, whereas categorical data were presented using frequency and percentage. The scales were scored using scoring algorithms described by the scale designers. Student's t-tests, ANOVA, Mann-Whitney, or Kruskal-Wal-

is tests were performed when appropriate to compare mean scores across subgroups. Regression analyses were used to examine the relationships between differences in the utility-weighted EQ-5D<sub>ST</sub> and demographics, clinical response and HRQL measures. Several selection procedures (backward, stepwise) were tested in order to check the robustness of the model. The impact of each predictor was assessed with estimates and their 95% confidence interval. The data were analysed using the SAS software version 8.2. For all tests, the type I error was set to 0.05.

## Results

### Sample characteristics

Ninety-five physicians enrolled 250 patients between May and November 2002. Patient age ranged from 18 to 92 years, with a mean of  $44.2 \pm 14.1$  years (mean  $\pm$  standard deviation). The sex ratio (males/females) was 0.4. The mean MADRS score was  $32.7 \pm 7.7$ , ranging from 13 to 53. This high level of severity was also revealed by the CGI: about 85% of patients were rated "markedly ill" or more severely. The demographic and clinical characteristics of the sample are reported in Table 1.

Among the 250 included patients, 24 were lost to follow-up (9.6%). Their sociodemographics and clinical charac-

**Table 2: EQ-5D dimension scores at baseline, D28 and D56**

	Baseline		D28		D56	
	N	%	N	%	N	%
<b>Mobility</b>						
No difficulties	166	73.5	192	85.0	207	91.6
Some difficulties	58	25.6	34	15.0	19	8.4
Extreme difficulties	2	0.9	0	0.0	0	0.0
<b>Self-care</b>						
No difficulties	186	82.3	214	94.7	216	95.6
Some difficulties	38	16.8	12	5.3	10	4.4
Extreme difficulties	2	0.9	0	0.0	0	0.0
<b>Usual activities</b>						
No difficulties	56	24.8	133	58.9	172	76.1
Some difficulties	150	66.4	92	40.7	53	23.5
Extreme difficulties	20	8.8	1	0.4	1	0.4
<b>Pain/Discomfort</b>						
No difficulties	54	23.9	114	50.4	135	59.8
Some difficulties	153	67.7	108	47.8	90	39.8
Extreme difficulties	19	8.4	4	1.8	1	0.4
<b>Anxiety/Depression</b>						
No difficulties	2	0.9	27	11.9	72	31.9
Some difficulties	48	21.2	155	68.6	133	58.8
Extreme difficulties	176	77.9	44	19.5	21	9.3

teristics were not significantly different from those of the 226 completers, so that all subsequent analyses were performed on the completers sub-sample.

#### **Impact of MDD on HRQL**

At baseline, the mean QLDS score was  $20.8 \pm 5.8$ , ranging from 5 to 31. The mean SF-36 dimension scores for the total sample were: PF  $69.0 \pm 24.5$ , RP  $22.4 \pm 30.7$ , BP  $52.0 \pm 23.5$ , GH  $38.3 \pm 17.3$ , VT  $22.2 \pm 13.1$ , MH  $24.5 \pm 12.1$ , RE  $9.1 \pm 21.3$  and SF  $30.2 \pm 17.1$ . The mean SF-36 summary scores were PCS  $43.6 \pm 9.2$  and MCS  $21.1 \pm 6.6$ . The mean EQ-5D<sub>ST</sub> score was  $0.33 \pm 0.25$ , ranging between -0.59 and 0.85. It was noteworthy that 8% of the study population had an EQ-5D<sub>ST</sub> score of worse than death, i.e. less than zero.

During follow-up, all the dimensions rated improved (Table 2). The mean EQ-5D<sub>ST</sub> scores were  $0.68 \pm 0.24$  (range: [-0.11; 1.00]) and  $0.78 \pm 0.21$  (range: [-0.08; 1.00]) at weeks 4 and 8, respectively.

#### **Comparison of EQ-5D<sub>ST</sub> by demographic and clinical features**

No significant differences were found in EQ-5D<sub>ST</sub> by demographics characteristics (Table 3): men and women reported the same preference-based score at baseline ( $0.32 \pm 0.22$  vs.  $0.32 \pm 0.26$ , respectively) and their scores increased in a similar manner during follow-up. Younger patients reported higher utility scores than older patients

at baseline, day 28 and day 56, although this pattern was not statistically significant.

Significant differences in EQ-5D<sub>ST</sub> were found by disease severity level assessed by CGI-S, with more severe patients having lower weighted index scores. At baseline, a mean difference of 0.12 was observed between "slightly/moderately ill" and "markedly ill" patients ( $p < 0.05$ ), and 0.18 between "markedly ill" and "seriously ill" patients ( $p < 0.001$ ). At the end of the follow-up, a mean difference of 0.12 was observed between patients with "first signs of illness" and "slightly/moderately ill" patients ( $p < 0.001$ ). "Slightly/moderately ill" and "markedly ill" patients had EQ-5D<sub>ST</sub> scores that differed 0.30 on average ( $p < 0.001$ ). A mean difference of 0.14 between "markedly ill" patients and "seriously ill" patients was found ( $p < 0.05$ ).

#### **Comparison of EQ-5D<sub>ST</sub> by clinical response**

Clinical response, defined by MADRS scores, revealed statistically significant differences between mean EQ-5D<sub>ST</sub> scores at baseline ( $p < 0.01$ ), D28 ( $p < 0.001$ ) and D56 ( $p < 0.001$ ) (Table 4).

At baseline, an overall significant difference was found in comparing the three groups, with a mean difference of 0.14 observed between "Responder remitters" and "Responder non-remitters" ( $p < 0.01$ ). During the study period, EQ-5D<sub>ST</sub> scores increased in all groups of clinical response. At the end of the follow-up, a statistically significant mean difference of 0.14 was observed between

**Table 3: Differences on utility score by demographic and clinical characteristics**

	Baseline		D28		D56	
	Mean $\pm$ SD	p	Mean $\pm$ SD	p	Mean $\pm$ SD	p
<b>Gender</b>		0.94		0.48		0.70
Male	0.32 $\pm$ 0.22		0.66 $\pm$ 0.24		0.79 $\pm$ 0.20	
Female	0.32 $\pm$ 0.26		0.68 $\pm$ 0.25		0.77 $\pm$ 0.21	
<b>Age group</b>		0.76		0.12		0.64
$\leq 30$ years	0.35 $\pm$ 0.23		0.76 $\pm$ 0.24		0.81 $\pm$ 0.23	
31–65 years	0.32 $\pm$ 0.24		0.66 $\pm$ 0.25		0.77 $\pm$ 0.21	
$> 65$ years	0.30 $\pm$ 0.38		0.68 $\pm$ 0.17		0.79 $\pm$ 0.14	
<b>Place of residence</b>		0.44		$< 0.01$		0.23
Urban area	0.31 $\pm$ 0.25		0.65 $\pm$ 0.25		0.77 $\pm$ 0.21	
Rural area	0.34 $\pm$ 0.25		0.75 $\pm$ 0.22		0.81 $\pm$ 0.19	
<b>CGI-Severity</b>		$< 0.001$		$< 0.001$		$< 0.001$
First signs	--		0.80 $\pm$ 0.14		0.86 $\pm$ 0.13	
Slightly/ Moderately ill	0.45 $\pm$ 0.22		0.66 $\pm$ 0.23		0.74 $\pm$ 0.19	
Markedly ill	0.33 $\pm$ 0.24		0.40 $\pm$ 0.26		0.44 $\pm$ 0.27	
Seriously ill	0.15 $\pm$ 0.21		0.14 $\pm$ 0.14		0.30 $\pm$ 0.27	

**Table 4: Utility scores and clinical response during the study period**

	Baseline		D28		D56	
	Mean $\pm$ SD	p	Mean $\pm$ SD	p	Mean $\pm$ SD	p
<b>Clinical response</b>		$< 0.01$		$< 0.001$		$< 0.001$
Responder remitters	0.35 $\pm$ 0.24		0.76 $\pm$ 0.18		0.85 $\pm$ 0.13	
Responders non-remitter	0.21 $\pm$ 0.25		0.54 $\pm$ 0.26		0.72 $\pm$ 0.20	
Non-responders	0.30 $\pm$ 0.27		0.54 $\pm$ 0.30		0.58 $\pm$ 0.28	

"Responder remitters" and "Responders non-remitter" ( $p < 0.001$ ). "Responders non-remitter" and "Non-responders" had EQ-5D<sub>ST</sub> scores that significantly differed by 0.14 on average ( $p < 0.05$ ).

### Comparison of Patient Reported Outcomes

At each visit, EQ-5D<sub>ST</sub> scores were compared with SF-36 dimension, SF-36 summary and QLDS scores (Table 5) by computing correlation coefficients. The correlation between EQ-5D<sub>ST</sub> score and the Mental Health dimension of the SF-36 was the highest observed, whatever the assessment (D0:  $r = 0.49$ ; D28:  $r = 0.56$ ; D56:  $r = 0.63$ ). At baseline, Pearson correlation coefficients were always greater than 0.30, except for the role-physical and role-emotional dimensions.

The QLDS was significantly correlated with the EQ-5D<sub>ST</sub> scores, ranging from -0.43 at baseline to -0.68 at the end of the follow-up period.

### Multivariate analysis

An ordinary least-square regression analysis to predict EQ-5D<sub>ST</sub> using demographic features, clinical and HRQL evolution only explained 40% of the variance in the weighted index scores. The statistically significant predictors in the regression model were differences in Physical Functioning, Bodily Pain, General Health and Mental Health (Table 6).

### Discussion

This study evaluated the usefulness of EQ-5D in assessing health status of primary care patients with major depressive disorder.

The sampling of our study is representative of the primary care depressed population in France [2]. 8% of the patients rated their health state as worse than death. This result is not surprising given the relationship between depression and suicide [31,32]. Despite different approaches to measuring health state utilities using standard gamble, time trade-off or rating scales, the findings of

**Table 5: Association between utility score and HRQL**

	Baseline Correlation	D28 Correlation	D56 Correlation
<b>Short Form-36 Item</b>			
Physical Functioning	0.39***	0.42***	0.45***
Role-Physical Limitations	0.28***	0.51***	0.47***
Bodily Pain	0.37***	0.53***	0.53***
General Health	0.47***	0.54***	0.58***
Vitality	0.45***	0.54***	0.59***
Mental Health	0.49***	0.56***	0.63***
Role-Emotional Limitations	0.26***	0.46***	0.49***
Social Functioning	0.44***	0.54***	0.59***
Physical Composite Summary	0.42***	0.51***	0.50***
Mental Composite Summary	0.34***	0.49***	0.58***
<b>Quality of Life for Depression Scale</b>	-0.43***	-0.59***	-0.68***

\*\*\* p &lt; 0.001

**Table 6: Contributors of the difference in EQ-5D<sub>ST</sub> during the study period**

	Parameter estimate	Standard error	p-value	95% Confidence Interval
Intercept	0.1971	0.0291	<0.001	[0.1396–0.2546]
Physical Functioning	0.0019	0.0007	<0.01	[0.0005–0.0033]
Bodily Pain	0.0016	0.0007	<0.05	[0.0001–0.0030]
General Health	0.0030	0.0009	<0.01	[0.0011–0.0048]
Mental Health	0.0044	0.0009	<0.001	[0.0027–0.0061]

our study agree with those previously reported: the baseline mean utility of an untreated depression was 0.33, compared to 0.30 for Revicki [21] and 0.32 for Bennett [33]. Patient-rated EQ-5D<sub>ST</sub> scores after the eight-week follow-up period was 0.78, which is comparable to utilities reported in other studies (0.79 [33]; 0.74 [21]; 0.76 [34]; 0.70 [35]). The main interest is that EQ-5D<sub>ST</sub> values are easy to collect in large sample surveys due to the brevity of EQ-5D classification system with its 5 dimensions and 3 levels.

No differences in EQ-5D<sub>ST</sub> utilities were observed by demographic characteristics, which is comparable to previous results in depressed patients [21,34,35]. More severely depressed patients reported utilities that were 0.30 points lower than less severely depressed patients at baseline. Several researchers have suggested that differences in utility greater than 0.05 are clinically important [12,36]. These findings may reflect clinically important differences.

As demonstrated in previous studies [21,37], we found that the EQ-5D<sub>ST</sub> score and other HRQL measures shared

only about 40% of variance. Utilities measure a patient's preference for their health state, while HRQL scales assess the patient's report of their functioning and well-being. Although these two concepts are related they are not identical [38], and measuring both may lead to a better understanding of reasons for non-compliance to treatment regimens.

There are several limitations that need to be considered when interpreting the results of this study. First, the study does not take into account the antidepressant prescribed or their side effects, which may influence patients' ratings [21,39]. Second, the concomitant impact of depression and chronic medical conditions could not be examined in this sample. It is likely that the health state utilities of patients with depression, in addition to a chronic medical disease would be significantly reduced [17]. Lastly, a limitation of the analysis presented in this study relates to the source of the utility weights used to compute the EQ-5D<sub>ST</sub>. Given that this was a national study conducted in France it may have been better to use social preference values based on the French population. Unfortunately, at the time of writing these values were not available for EQ-

5D<sub>ST</sub>. Weights were therefore adopted from a major UK study that provided the most robust technical estimates widely used in the evaluation of EQ-5D<sub>ST</sub> in countries that lack their own national reference data.

Utility scores are needed for calculating QALYs, which are used as indicators of effectiveness or outcome in economic evaluations [35,36,40]. It is debatable whether or not patient or general population utilities should be used in cost-effectiveness studies [40]. Nevertheless, patients with experience in the disease may be the best providers of health state preference data. Cost-effectiveness studies are required to help clinicians and health care decision-makers in determining the impact of new antidepressants on both patient outcomes and medical or overall societal costs. Understanding patient preferences for depression outcomes is important for economic evaluations of new antidepressants, as well as for understanding patient behaviour and compliance to antidepressant regimens. Such a measure can be applied to cost-utility analyses either within clinical decision modelling studies or within prospective, randomised clinical trials and offers additional scope for the analysis and reporting of data derived from clinical trials of new compounds.

## Acknowledgment

Funding for this study was provided by H. Lundbeck A/S.

## References

- Williams JW Jr, Kerber CA, Mulrow CD, Medina A, Aguilar C: **Depressive disorders in primary care: prevalence, functional disability and identification.** *J Gen Intern Med* 1995, **10**:7-12.
- Le Pape A, Lecomte T: **Prévalence et prise en charge de la dépression.** Paris: Centre de Recherche en Economie de la Santé 1999.
- Hays RD, Wells KB, Sherbourne CD, Rogers W, Spritzer K: **Functioning and well-being outcomes of patients with depression compared with chronic general medical illnesses.** *Arch Gen Psychiatry* 1995, **52**:11-9.
- Saarijarvi S, Salminen JK, Toikka T, Raitasalo R: **Health-related quality of life among patients with major depression.** *Nord J Psychiatry* 2002, **56**:261-4.
- Lecrubier Y: **The burden of depression and anxiety in general medicine.** *J Clin Psychiatry* 2001, **62**:4-9.
- Goff VV: **Depression: a decade of progress, more to do.** *NHPF Issue Brief* 2002, **786**:1-14. (Nov 22)
- Nierenberg AA: **Current perspectives on the diagnosis and treatment of major depressive disorder.** *Am J Manag Care* 2001, **7**:S353-66.
- Brown C, Schulberg HC, Prigerson HG: **Factors associated with symptomatic improvement and recovery from major depression in primary care patients.** *Gen Hosp Psychiatry* 2000, **22**:242-50.
- Revicki DA, Simon GE, Chan K, Katon W, Heiligenstein J: **Depression, health-related quality of life, and medical cost outcomes of receiving, recommended levels of antidepressant treatment.** *J Fam Pract* 1998, **47**:446-52.
- Reynolds CF 3rd: **Treatment of major depression in late life: a life cycle perspective.** *Psychiatr Q* 1997, **68**:221-46.
- Weinstein MC, Siegel JE, Gold MR, Kamlet MS, Russell LB: **Recommendations of the Panel on Cost-Effectiveness in Health and Medicine.** *JAMA* 1996, **276**:1253-8.
- Bennett KJ, Torrance GW: **Measuring health state preferences and utilities: rating scale, time trade-off and standard gamble techniques.** In: *Quality of Life and Pharmacoeconomics in Clinical Trials* 2nd edition. Edited by: Spilker B. Philadelphia: Lipincott-Raven; 1996.
- de Boer AG, Stalmeier PF, Sprangers MA, de Haes JC, van Sandick JW, Hulscher JB, van Lanschot JJ: **Transhiatal vs extended transthoracic resection in oesophageal carcinoma: patients' utilities and treatment preferences.** *Br J Cancer* 2002, **86**:851-7.
- Tosteson AN, Hammond CS: **Quality-of-life assessment in osteoporosis: health-status and preference-based measures.** *Pharmacoeconomics* 2002, **20**:289-303.
- Smith DS, Krygiel J, Nease RF Jr, Sumner W 2nd, Catalona WJ: **Patient preferences for outcomes associated with surgical management of prostate cancer.** *J Urol* 2002, **167**:2117-22.
- Chouinard G, Albright PS: **Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol.** *J Clin Psychopharmacol* 1997, **17**:298-307.
- Wells KB, Sherbourne CD: **Functioning and utility for current health status of patients with depression or chronic medical conditions in managed, primary care practices.** *Arch Gen Psychiatry* 1999, **56**:897-904.
- Bennett KJ, Torrance GW, Boyle MH, Guscott R: **Cost-utility analysis in depression: the McSad utility measure for depression health state.** *Psychiatr Serv* 2000, **51**:1171-6.
- Schaffer A, Levitt AJ, Hershtok SK, Oh P, MacDonald C, Lancot K: **Utility scores of symptom profiles in major depression.** *Psychiatry Res* 2002, **110**:189-97.
- Lenert LA, Morss S, Goldstein MK, Bergen MR, Faustman WO, Garber AM: **Measurement of the validity of utility elicitation performed by computerized interview.** *Med Care* 1997, **35**:915-20.
- Revicki DA, Wood M: **Patient-assigned health state utilities for depression-related outcomes: differences by depression severity and antidepressant medications.** *J Affect Disord* 1998, **48**:25-36.
- Committee for Proprietary Medicinal Products: **Note for Guidance on Clinical Assessment of Medicinal Products in the Treatment of Depression.** London: EMEA 2002.
- American Psychiatric Association: **Diagnostic and Statistical Manual of Mental Disorders.** Washington DC: American Psychiatric Association 1994.
- Montgomery SA, Asberg M: **A New Depression Scale Designed to be Sensitive to Change.** *Br J Psychiatry* 1979, **134**:382-9.
- Léplège A, Ecosse E, Verdier A, Perneger TV: **The French SF-36 Health Survey: translation, cultural adaptation and preliminary psychometric evaluation.** *J Clin Epidemiol* 1998, **51**:1013-23.
- Ware JE Jr, Gandek B, Kosinski M, Aaronson NK, Apolone G, Brazier J, Bullinger M, Kaasa S, Léplège A, Prieto L, Sullivan M, Thunéborg K: **The equivalence of SF-36 summary health scores estimated using standard and country-specific algorithms in 10 countries.** *J Clin Epidemiol* 1998, **51**:1167-70.
- Hunt SM, McKenna SP: **The QLDS, a scale for the measurement of quality of life in depression.** *Health Policy* 1992, **22**:307-19.
- McKenna SP, Doward LC, Kohlmann T, Mercier C, Niero M, Paes M, Patrick D, Ramirez N, Thorsen H, Whalley D: **International development of the Quality of Life in Depression Scale (QLDS).** *J Affect Disord* 2001, **63**:189-99.
- EuroQoL Group: **EuroQoL – a new facility for the measurement of health-related quality of life.** *Health Policy* 1990, **16**:199-208.
- Dolan P, Gudex C, Kind P, Williams A: **A social tariff for EuroQoL: Results from a UK General Population Survey.** University of York: Center for Health Economics 1995.
- Kohn Y, Zislin J, Agid O, Hanin B, Troudard T, Shapira B, Bloch M, Gur E, Ritsner M, Lerer B: **Increased prevalence of negative life events in subtypes of major depressive disorder.** *Compr Psychiatry* 2001, **42**:57-63.
- Angst J, Angst F, Stassen HH: **Suicide risk in patients with major depressive disorder.** *J Clin Psychiatry* 1999, **60**:57-62.
- Bennett KJ, Torrance GW, Boyle MH, Guscott R, Moran LA: **Development and testing of a utility measure for major, unipolar depression (McSad).** *Qual Life Res* 2000, **9**:109-20.
- Pyne JM, Patterson TL, Kaplan RM, Ho S, Gillin JC, Goldshan S, Grant I: **Preliminary longitudinal assessment of quality of life in patients with major depression.** *Psychopharmacol Bull* 1997, **33**:23-9.
- Pyne JM, Patterson TL, Kaplan RM, Gillin JC, Koch WL, Grant I: **Assessment of quality of life of patients with major depression.** *Psychiatr Serv* 1997, **48**:224-30.
- Torrance GW, Feeny D: **Utilities and quality-adjusted life years.** *Int J Technol Assess Health Care* 1989, **5**:559-75.



37. Revicki DA, Kaplan RM: **Relationship between psychometric and utility-based approaches to the measurement of health-related quality of life.** *Qual Life Res* 1993, **2**:477-87.
38. Apolone G, De Carli G, Brunetti M, Garattini S: **Health-related quality of life (HR-QOL) and regulatory issues. An assessment of the EMEA recommendations on the use of HR-QOL measures in drug approval.** *Pharmacoeconomics* 2001, **19**:187-95.
39. Simon GE, VonKorff M, Heiligenstein JH, Revicki DA, Grothaus L, Katon W, Wagner EH: **Initial antidepressant choice in primary care: effectiveness and cost of fluoxetine versus tricyclic antidepressants.** *JAMA* 1996, **275**:1897-902.
40. Gold MR, Siegel JE, Russell LB, Weinstein MC, eds: **Cost-Effectiveness in Health and Medicine.** New York: Oxford University Press; 1996.

Publish with **BioMed Central** and every scientist can read your work free of charge

*"BioMed Central will be the most significant development for disseminating the results of biomedical research in our lifetime."*

Sir Paul Nurse, Cancer Research UK

Your research papers will be:

- available free of charge to the entire biomedical community
- peer reviewed and published immediately upon acceptance
- cited in PubMed and archived on PubMed Central
- yours — you keep the copyright

Submit your manuscript here:  
[http://www.biomedcentral.com/info/publishing\\_adv.asp](http://www.biomedcentral.com/info/publishing_adv.asp)

